HEMATOLOGIC OUTCOMES AND DOSING PATTERNS IN ANEMIC PATIENTS WITH PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) SWITCHING FROM DARBEPOETIN ALFA (DARB) TO EPOETIN ALFA (EPO)

被引：0

作者：

Hura, Claudia ^{[1
]}

Jackson, James ^{[2
]}

Lunacsek, Orsolya ^{[2
]}

Bailey, Robert A. ^{[3
]}

McKenzie, R. Scott ^{[3
]}

机构：

[1] San Antonio Kidney Dis Ctr, San Antonio, TX USA

[2] Xcenda LLC, Palm Harbor, FL USA

[3] Centocor Ortho Biotech Serv LLC, Horsham, PA USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2010年 / 55卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

133

引用

页码：A65 / A65

页数：1

共 50 条

[41] DOSING PATTERN AND COST COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA IN CHRONIC KIDNEY DISEASE AND CHEMOTHERAPY-INDUCED ANEMIA INPATIENTS
Lafeuille, M. H.
Bailey, R. A.
Senbetta, M.
McKenzie, R. S.
Lefebvre, P.
VALUE IN HEALTH, 2011, 14 (03) : A161 - A161
[42] Pharmacokinetics (PK) of Aranesp® (darbepoetin alfa) in patients with chronic kidney disease (CKD)
Padhi, D
Jang, G
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V255 - V255
[43] Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis - Author's reply
Scott, SD
PHARMACOTHERAPY, 2003, 23 (05): : 693 - 694
[44] Final hematologic results:: Epoetin alfa (EPO) 40,000 U QW vs darbepoetin alfa (DARB) 200 μg Q2W in anemic cancer patients (pts) receiving chemotherapy (CT).
Waltzman, RJ
Croot, C
Williams, D
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 736S - 736S
[45] ECONOMIC EVALUATION OF DARBEPOETIN ALFA AND EPOETIN IN HEMODIALYSIS PATIENTS WITH ANEMIA AND CHRONIC KIDNEY DISEASE
Vorobiev, P.
Lesnicheva, M.
Avksentieva, M.
Nekrasova, N.
VALUE IN HEALTH, 2009, 12 (03) : A134 - A134
[46] Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review
Germain, M
Ram, CV
Bhaduri, S
Tang, KL
Klausner, M
Curzi, M
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (10) : 2146 - 2152
[47] Greater area under the hemoglobin change curve is associated with improved outcomes in patients receiving epoetin alfa (EPO) or darbepoetin alfa (DARB) for chemotherapy-related anemia (CRA).
Lefebvre, P
Duh, MS
McKenzie, RS
Mody, SH
Woodman, RC
Williams, D
PHARMACOTHERAPY, 2005, 25 (10): : 1469 - 1469
[48] Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis
Macdougall, IC
Matcham, J
Gray, SJ
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (03) : 576 - 581
[49] EPOETIN ALFA UTILIZATION FROM 2000 THROUGH 2007 FOR CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
Lafeuille, Marie-Helene
Bailey, Robert A.
McKenzie, R. Scott
Vekeman, Francis
Picch, Catherine Tak
Lefebvre, Patrick
AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (04) : A50 - A50
[50] Darbepoetin alfa maintains mean hemoglobin (Hb) levels in chronic kidney disease (CKD) patients who are erythropoietin (EPO)-naive or are converting from EPO therapy
Hertel, J
Locay, H
Scarlata, D
Jackson, L
Brenner, R
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (04) : A25 - A25

← 1 2 3 4 5 →